...
首页> 外文期刊>Nature Communications >DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing
【24h】

DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing

机译:DNA / RNA异源双链寡核苷酸可实现高效基因沉默

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Antisense oligonucleotides (ASOs) are recognized therapeutic agents for the modulation of specific genes at the post-transcriptional level. Similar to any medical drugs, there are opportunities to improve their efficacy and safety. Here we develop a short DNA/RNA heteroduplex oligonucleotide (HDO) with a structure different from double-stranded RNA used for short interfering RNA and single-stranded DNA used for ASO. A DNA/locked nucleotide acid gapmer duplex with an α-tocopherol-conjugated complementary RNA (Toc-HDO) is significantly more potent at reducing the expression of the targeted mRNA in liver compared with the parent single-stranded gapmer ASO. Toc-HDO also improves the phenotype in disease models more effectively. In addition, the high potency of Toc-HDO results in a reduction of liver dysfunction observed in the parent ASO at a similar silencing effect. HDO technology offers a novel concept of therapeutic oligonucleotides, and the development of this molecular design opens a new therapeutic field.
机译:反义寡核苷酸(ASO)是公认的用于在转录后水平上调节特定基因的治疗剂。类似于任何医用药物,都有机会提高其功效和安全性。在这里,我们开发了一种短DNA / RNA异源双链寡核苷酸(HDO),其结构不同于用于短干扰RNA的双链RNA和用于ASO的单链DNA。与母体单链gapmer ASO相比,具有α-生育酚偶联的互补RNA(Toc-HDO)的DNA /锁定核苷酸裂隙肽双链体在降低肝脏中靶标mRNA的表达上具有更大的效力。 Toc-HDO还可以更有效地改善疾病模型的表型。此外,Toc-HDO的高效力可降低母体ASO中观察到的肝功能障碍,并具有类似的沉默效果。 HDO技术提供了治疗性寡核苷酸的新概念,这种分子设计的发展打开了一个新的治疗领域。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号